BeiGene Archives -

Market Access/ News/ News/ News/ Oncology

NICE says yes to BeiGene’s Brukinsa after Scottish nay

Phil Taylor BeiGene, Brukinsa, HEOR, NICE, non-Hodgkin lymphoma, Oncology, UK 0 Comment

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine

NICE says yes to BeiGene’s Brukinsa after Scottish nay

https://pharmaphorum.com/news/nice-says-yes-to-beigenes-brukinsa-after-scottish-nay/

News/ News/ News/ Oncology/ R&D

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Phil Taylor BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab 0 Comment

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

https://pharmaphorum.com/oncology/novartis-eyes-earlier-use-of-pd-1-drug-in-oesophageal-cancer/

News/ News/ Oncology

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Phil Taylor BeiGene, immuno-oncology, Non-small cell lung cancer, Novartis, ociperlimab, Oncology, PD-1, TIGIT, tislelizumab 0 Comment

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

https://pharmaphorum.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug/

News/ News/ Oncology/ Top stories

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

Phil Taylor BeiGene, fda, immuno-oncology, Novartis, oesophageal cancer, Oncology 0 Comment

Novartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

https://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/

News/ News/ Oncology

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

Phil Taylor AbbVie, AstraZeneca, BeiGene, Brukinsa, Calquence, chronic lymphocytic leukaemia, Haematology, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

https://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/

News/ News/ Oncology/ Top stories

FDA fast-tracks Leap’s gastric cancer immunotherapy

Phil Taylor BeiGene, gastric cancer, immuno-oncology, Leap Therapeutics, Oncology 0 Comment

Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric

FDA fast-tracks Leap’s gastric cancer immunotherapy

https://pharmaphorum.com/news/fda-fast-tracks-leaps-gastric-cancer-immunotherapy/

News/ News/ Oncology

Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market

Richard Staines BeiGene, Boehringer Ingelheim, cancer 0 Comment

Boehringer Ingelheim is to manufacture the first biologic drug approved in China using a new regulatory system, designed

Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market

https://pharmaphorum.com/news/boehringer-gets-clearance-to-manufacture/

News/ News/ News/ Oncology/ R&D

BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WM

Richard Staines AbbVie, BeiGene, Brukinsa, Imbruvica, Johnson & Johnson 0 Comment

BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white

BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WM

https://pharmaphorum.com/news/beigenes-brukinsa-fails-to-beat-abbvie-jjs-ibrutinib-in-wm/

Market Access/ News/ News

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

Phil Taylor AbbVie, AstraZeneca, BeiGene, Brukinsa, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson 0 Comment

AbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

https://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/

Trending

BeiGene

Login